Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

Slides:

Advertisements

Similar presentations

Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,

Advertisements

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.

Volume 149, Issue 6, Pages (November 2015)

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Nathalie Adda, Doug J. Bartels, Linda Gritz, Tara L

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update Emmet B. Keeffe, Douglas T. Dieterich,

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Effectiveness of Hepatitis B Treatment in Clinical Practice

Volume 153, Issue 4, Pages (October 2017)

Volume 146, Issue 3, Pages e1 (March 2014)

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus Amit G. Singal, Michael.

Michael Biermer, Thomas Berg Gastroenterology

Volume 134, Issue 5, Pages (May 2008)

Clinical Challenges and Images in GI

Unusual Case of an Upset Stomach

Volume 135, Issue 4, Pages (October 2008)

A Historical Perspective on Clinical Advances in Pancreatic Diseases

Volume 150, Issue 4, Pages (April 2016)

Volume 154, Issue 4, Pages (March 2018)

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse

Yasuhiko Sugawara, Masatoshi Makuuchi

Volume 155, Issue 5, Pages e2 (November 2018)

Jean-Michel Pawlotsky Gastroenterology

Volume 141, Issue 5, Pages (November 2011)

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening Brianna L. Norton,

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B Jeong Han Kim, So Young Kwon, Young Sok.

From non-A, non-B hepatitis to hepatitis C virus cure

Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C Pamela S. Belperio, Elizabeth.

Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H

Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay? Brian J. McMahon, MD, Brenna C. Simons, PhD Clinical.

A. Sidney Barritt, Michael W. Fried Gastroenterology

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.

Endoscopic Therapy for Barrett's Esophagus

Why We Should Be Willing to Pay for Hepatitis C Treatment

Volume 142, Issue 6, Pages e3 (May 2012)

Volume 142, Issue 6, Pages (May 2012)

Rafael Esteban, Maria Buti Gastroenterology

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Volume 140, Issue 7, Pages (June 2011)

Volume 152, Issue 1, Pages (January 2017)

Volume 132, Issue 1, Pages 5-6 (January 2007)

Volume 148, Issue 3, Pages (March 2015)

Volume 67, Issue 5, Pages (November 2017)

Genetic Factors and Hepatitis C Virus Infection

Volume 138, Issue 2, Pages (February 2010)

The Rise and Fall (and Rise?) of Endoscopic Anti-Reflux Procedures

Alan Bonder, MD, Nezam H. Afdhal, MD

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

The Dawning of a New Editorial Board for Gastroenterology

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Volume 139, Issue 1, Pages (July 2010)

Changing of the Guards: 2011–2016 Gastroenterology Team

Yun-Fan Liaw, Wen-Juei Jeng, Ming-Ling Chang Gastroenterology

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Clinical Gastroenterology and Hepatology

Volume 139, Issue 6, Pages e1 (December 2010)

Volume 139, Issue 5, Pages (November 2010)

Volume 147, Issue 6, Pages (December 2014)

Electronic Clinical Challenges and Images in GI

Controversies in Liver Transplantation for Hepatitis C

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Fasiha Kanwal, Tuyen Hoang, Timothy Chrusciel, Jennifer R

Presentation transcript:

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami, Norifumi Kawada Gastroenterology Volume 153, Issue 1, Pages 327-328 (July 2017) DOI: 10.1053/j.gastro.2017.03.075 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 The clinical course of a 74-year-old, anti-hepatitis C virus (HCV) treatment-naïve woman with chronic hepatitis C who achieved an sustained virologic response under ledipasvir plus sofosbuvir therapy. Serum HCV-RNA became negative after 8 weeks of treatment on the Roche TaqMan assay (lower limit of quantification [LLOQ], 1.2 log10 IU/mL), but remained positive during treatment and 4 weeks after the end of treatment, becoming negative 8 weeks after the end of treatment, as determined by the Abbott RealTime HCV assay (LLOQ, 1.08 log10 IU/mL). LDV, ledipasvir; SOF, sofosbuvir; TD, target detected, indicating HCV-RNA positive but < LLOQ; TND, target not detected, indicating HCV-RNA negative. Gastroenterology 2017 153, 327-328DOI: (10.1053/j.gastro.2017.03.075) Copyright © 2017 AGA Institute Terms and Conditions